Antibiotics are 42% more likely to be in shortage compared to all other drugs, according to the latest analysis from the U.S. Pharmacopeia’s (USP) Medicine Supply Vulnerability Insights Series. The findings are sourced from USP’s global Medicine Supply Map, derived from 40 external datasets and proprietary information about the use of USP quality standards, spanning 92% of generic medicines approved in the U.S.
5 Questions With Vimala Raghavendran, Senior Director and Head of USP Pharmaceutical Supply Chain Center
Vimala Raghavendran leads the U.S. Pharmacopeia (USP) Pharmaceutical Supply Chain Center, which houses the USP Medicine Supply Map, an information system that identifies, characterizes, and quantifies risk in the upstream pharmaceutical supply chain so that stakeholders can prioritize supply chain investments and prevent drug shortages.
U.S. Pharmacopeia is pleased to announce that Dr. Farah Towfic, PharmD, MBA, RPh, Director of CEO Operations has been recognized among 31 outstanding women recipients of the 2022 Women Making History Award for her extraordinary work as part of USP’s response to the COVID-19 crisis.
COVID Vaccines Demonstrated the Potential of mRNA Technology but Common Approaches for Managing Quality are Needed
U.S. Pharmacopeia (USP), a global independent scientific organization, is seeking scientific input on new draft guidelines, “Analytical Procedures for mRNA Vaccine Quality.” USP and a group of leading mRNA experts have identified the need for analytical procedures and best practices to support quality assessments for mRNA vaccines and therapies in development pipelines for infectious diseases, cancer, cystic fibrosis and other disorders.
The vast majority (95%) of U.S. physicians believe that the COVID-19 pandemic has revealed vulnerabilities in the medicines supply chain that are not going away, and seven out of 10 (73%) feel their trust in the ability of the supply chain to deliver safe, quality medicines has eroded, according to a survey released today by U.S. Pharmacopeia (USP), a global independent scientific organization. A large majority believe the responsibility for solutions falls on multiple stakeholders.
In 2020 we introduced the “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Since then, we have highlighted a plethora of professionals at all levels, from early career to the C-suite, from scientists to business developers to managers and directors, and all facets in between. To celebrate, we’d like to highlight the Top 5 most viewed interviews from 2021.
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. This week we welcome Ronald T. Piervincenzi, Ph.D., Chief Executive Officer, United States Pharmacopeia.
United States Pharmacopeia acquires Pharmatech Associates, Inc. to expand services that help ensure the quality of medicines
United States Pharmacopeia (USP), an independent, scientific nonprofit organization, is pleased to announce the acquisition of Pharmatech Associates, Inc. By adding Pharmatech Associates expertise, USP further advances its more than 200-year mission to help ensure access to quality medicines by extending services that assist manufacturers to meet global quality standards across the drug and product lifecycle.